It was reported that the treatment of early and moderate Alzheimer’s disease has largely involved the replacement of neurotransmitters that are known to be lacking, mostly based on AChE inhibition [33,34]. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.